101 related articles for article (PubMed ID: 10523677)
1. Adoptive therapy of canine metastatic mammary carcinoma with the human MHC non-restricted cytotoxic T-cell line TALL-104.
Visonneau S; Cesano A; Jeglum KA; Santoli D
Oncol Rep; 1999; 6(6):1181-8. PubMed ID: 10523677
[TBL] [Abstract][Full Text] [Related]
2. Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104.
Cesano A; Visonneau S; Wolfe JH; Jeglum KA; Fernandez J; Gillio A; O'Reilly RJ; Santoli D
Cancer Immunol Immunother; 1997 May; 44(3):125-36. PubMed ID: 9191872
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.
Cesano A; Visonneau S; Jeglum KA; Owen J; Wilkinson K; Carner K; Reese L; Santoli D
Cancer Res; 1996 Jul; 56(13):3021-9. PubMed ID: 8674057
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts.
Geoerger B; Tang CB; Cesano A; Visonneau S; Marwaha S; Judy KD; Sutton LN; Santoli D; Phillips PC
Neuro Oncol; 2000 Apr; 2(2):103-13. PubMed ID: 11303619
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104.
Visonneau S; Cesano A; Tran T; Jeglum KA; Santoli D
Clin Cancer Res; 1997 Oct; 3(10):1789-97. PubMed ID: 9815565
[TBL] [Abstract][Full Text] [Related]
6. Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer.
Cesano A; Wortman JA; Pourdehnad M; Visonneau S; Mozley D; Bhatnagar A; Alavi A; Santoli D
Int J Oncol; 1999 Feb; 14(2):233-44. PubMed ID: 9917497
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
[TBL] [Abstract][Full Text] [Related]
8. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice.
Cesano A; Visonneau S; Santoli D
Anticancer Res; 1998; 18(4A):2289-95. PubMed ID: 9703868
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
[TBL] [Abstract][Full Text] [Related]
10. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution of human MHC non-restricted TALL-104 killer cells in healthy and tumor bearing mice.
Cesano A; Visonneau S; Tran T; Santoli D
Int J Oncol; 1999 Feb; 14(2):245-51. PubMed ID: 9917498
[TBL] [Abstract][Full Text] [Related]
12. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells.
Wright SE; Rewers-Felkins KA; Quinlin IS; Fogler WE; Phillips CA; Townsend M; Robinson W; Philip R
Immunol Invest; 2008; 37(3):215-25. PubMed ID: 18389441
[TBL] [Abstract][Full Text] [Related]
13. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function.
Liu C; Yu S; Zinn K; Wang J; Zhang L; Jia Y; Kappes JC; Barnes S; Kimberly RP; Grizzle WE; Zhang HG
J Immunol; 2006 Feb; 176(3):1375-85. PubMed ID: 16424164
[TBL] [Abstract][Full Text] [Related]
14. Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.
Lei J; Wu Z; Jiang Z; Li J; Zong L; Chen X; Duan W; Xu Q; Zhang L; Han L; Ma Q; Wang Z; Zhang D
Oncotarget; 2016 Dec; 7(50):83601-83610. PubMed ID: 27876704
[TBL] [Abstract][Full Text] [Related]
15. Understanding of the immunological heterogeneity of canine mammary carcinomas to provide immunophenotypic features of circulating leukocytes as clinically relevant prognostic biomarkers.
Estrela-Lima A; Araújo MS; da Costa-Neto JM; Ribeiro LG; Damasceno KA; D'Assis MJ; Martins-Filho OA; Teixeira-Carvalho A; Serakides R; Cassali GD
Breast Cancer Res Treat; 2012 Feb; 131(3):751-63. PubMed ID: 21448671
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
17. Immunological aspects of mammary tumors in dogs and cats: a survey including own studies and pertinent literature.
Rutten VP; Misdorp W; Gauthier A; Estrada M; Mialot JP; Parodi AL; Rutteman GR; Weyer K
Vet Immunol Immunopathol; 1990 Nov; 26(3):211-25. PubMed ID: 2264285
[TBL] [Abstract][Full Text] [Related]
18. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice.
Sabzevari H; Reisfeld RA
Cancer Res; 1993 Oct; 53(20):4933-7. PubMed ID: 8402683
[TBL] [Abstract][Full Text] [Related]
19. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
[TBL] [Abstract][Full Text] [Related]
20. Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice.
Visonneau S; Cesano A; Torosian MH; Santoli D
Clin Cancer Res; 1997 Sep; 3(9):1491-500. PubMed ID: 9815835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
